Document:

EX-4.2

 Exhibit 4.2 

FIRST AMENDMENT TO THE 

VERIZON SAVINGS AND SECURITY PLAN 

FOR MID-ATLANTIC ASSOCIATES 

This Amendment is adopted this 13th day of May, 2015. 

WHEREAS, Verizon Communications Inc. (Verizon) maintains the Verizon Savings and Security Plan for
Mid-Atlantic Associates (Savings Plan); 
 WHEREAS, Section 20.1 of the Savings Plan
provides that the plan shall be automatically amended to incorporate any amendments required by the Internal Revenue Service as a condition for the issuance of a favorable determination letter on the qualified status of the plan; and 

WHEREAS, the Internal Revenue Service has requested certain amendments to the Savings Plan as a condition for the issuance of a
favorable determination letter. 
 NOW, THEREFORE, effective as of January 1, 2015, the Plan is hereby amended as follows. 

1.    The definition of “Value” in Section 2 of the Savings Plan is amended to read in its entirety as
follows. 
 Value 
  

	 	•	 	With respect to Verizon Shares Value shall be determined as of the Valuation Date for purposes of the valuation of Accounts under the Plan, and shall be determined as of the date of any purchase of Verizon Shares from
Verizon for purposes of Section 12 (“Duties of Trustee”), and shall mean market value based on the closing price per share on the applicable date. 

  

	 	•	 	With respect to Funds other than the Verizon Shares Fund or the Income Fund, Value shall be determined by the Trustee at the fair market value on the close of business on each Valuation Date. The Trustee in the
reasonable exercise of its discretion shall determine fair market value. 

  

	 	•	 	With respect to the assets of the Income Fund which are invested with one or more insurance companies or other financial institutions and guarantee by contract the repayment of principal plus a specified rate of
interest for a specified period of time shall be determined as of each Valuation Date by the Trustee based upon the principal then invested in the contracts plus accrued interest. 

 

	 	•	 	 With respect to other assets in the Income Fund such as U. S. Government, Government agency or corporate
market-value bonds, shall be determined on the Valuation Date by the Trustee based upon the value determined on the last Valuation Date of the prior month from the exchange on which they are primarily traded

	 	 
plus a crediting rate determined by the “wrapper” provider. For purposes of this definition, the term “wrapper” means a contract issued by a financial institution that
provides the guarantee that the liquidation value of the assets equals the book value in the event of benefit payments or contract maturity. The contract provides a guaranteed minimum crediting rate (no less than zero); treats participant
withdrawals and transfers at book value regardless of changes in interest rates that would otherwise affect the underlying value of the portfolio being wrapped; and transforms gains and losses in the underlying portfolio into adjustments to future
interest crediting rates. 

 2.    The definition of “Verizon Shares” in Section 2 of
the Savings Plan is amended to read in its entirety as follows. 
 Verizon Shares 

Verizon Shares shall mean the common shares of Verizon which are readily tradable on an established securities market and which constitute
“employer securities” as defined by Code section 409(l). 
 3.    Section 6.3.3 of the Plan is amended to read
in its entirety as follows. 
 6.3.3    Correcting Excess Annual Additions 

Section 31.4 of the Plan sets forth the provisions that apply to the correction of Annual Additions which exceed the applicable limitation
under Code section 415. 
 4.    Section 6.3.4 of the Plan is hereby deleted and Section 6.3.5 is renumbered as
Section 6.3.4. 
 IN WITNESS WHEREOF, this Amendment has been executed as of the date first set forth above. 

 

			
		 	Verizon Communications Inc.
		
	By:	 	 /s/ Marc Schoenecker

		 	Marc Schoenecker
		
		 	Legal Counsel to the Verizon Employee Benefits CommitteeEX-4.3

 Exhibit 4.3 

SECOND AMENDMENT TO THE 

VERIZON SAVINGS AND SECURITY PLAN 

FOR MID-ATLANTIC ASSOCIATES 

This Amendment is adopted this 7th day of July, 2016. 

WHEREAS, Verizon Communications Inc. (Verizon) maintains the Verizon Savings and Security Plan for
Mid-Atlantic Associates (Savings Plan); 
 WHEREAS, Section 20.1 of the Savings Plan
provides that the plan shall be automatically amended to incorporate any amendments required by a collective bargaining agreement; and 

WHEREAS, recently approved collective bargaining agreements provide for the amendment of the Savings Plan to include diversification
and automatic enrollment provisions. 
 NOW, THEREFORE, the Plan is hereby amended as follows effective as specified below. 

1.    Effective 90 days following the June 17, 2016 effective date of the applicable collective bargaining
agreements, Article 3 of the Plan is amended to add a new Section 3.6 at the end of such Article, such new Section to read in its entirety as follows: 

3.6    Automatic Enrollment 

A newly hired Eligible Employee who does not make an affirmative contribution election (including an affirmative election not to contribute to
the Plan) before the end of the opt-out period specified in a notice provided by the Administrator shall be deemed to have filed an Approved Form of Timely Prior Notice to contribute Basic Tax-Deferred Contributions (not Roth Elective Contributions) equal to 6% of the Eligible Employee’s Basic Weekly Pay and to have such contributions invested in the Fund designated by the Administrator as a
qualified default investment alternative. References herein to elected Employee Contributions include contributions deemed elected by an Eligible Employee pursuant to this Section. 

2.    Effective 90 days following the June 17, 2016 effective date of the applicable collective bargaining
agreements, Section 4.4 of the Plan is amended to read in its entirety as follows: 
 4.4    Commencement of
Contributions 
 The Employee Contributions which are affirmatively elected by an Eligible Employee will begin as soon as
administratively possible on or after the Enrollment Date on which the Eligible Employee begins participation in the Plan pursuant to Section 3.5 (“Voluntary Election to Participate”). The Employee Contributions deemed elected by an
Eligible Employee 

 
pursuant to Section 3.6 (“Automatic Enrollment”) will begin no later than the second payroll that occurs 45 days after the Eligible Employee’s hire date unless the Eligible
Employee makes a different affirmative election during the applicable opt-out period. 

3.    Effective 30 days following the June 17, 2016 effective date of the applicable collective bargaining
agreements, Section 8.3 of the Plan is amended to read in its entirety as follows: 
 8.3    Diversification of
Amounts in ESOP Employing Company Matching Allocations Account 
 A Participating Employee shall be permitted to direct, by giving an
Approved Form of Timely Prior Notice, that up to 100% of his ESOP Allocation Contributions Account and ESOP Employing Company Matching Allocations Account be transferred in 1% increments among the other investment funds available under the Plan in
the manner described in Section 8.2 (“Change in Investment Direction”). 
 4.    Effective 30 days
following the June 17, 2016 effective date of the applicable collective bargaining agreements, the reference to “Section 8.3.2” in Section 33.3.2 of the Plan shall be revised to refer to “Section 8.3.” 

IN WITNESS WHEREOF, this Amendment has been executed as of the date first set forth above. 

 

			
		 	Verizon Communications Inc.
		
	By:	 	 /s/ Marc Schoenecker

		 	Marc Schoenecker
		
		 	Legal Counsel to the Verizon Employee Benefits Committeesndx-ex1034_508.htm

 

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Exhibit 10.34

AMENDMENT NO. 9 TO CLINICAL TRIAL AGREEMENT BETWEEN

ECOG-ACRIN CANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC.

 

This Amendment No. 9 to Clinical Trial Agreement (the "Amendment" or "Amendment 9") is entered into as of November 22, 2017 (the "Effective Date"), by and between ECOG-ACRIN Cancer Research Group, on behalf of itself and its member hospitals, institutions and physicians (the "Group," "ECOG" or "ECOG-ACRIN"), and Syndax Pharmaceuticals, Inc. ("Company" or "Syndax").

 

WITNESSETH:

 

WHEREAS, pursuant to the Clinical Trial Agreement dated March 14, 2014 between the parties ("Agreement"), the parties agreed to certain terms specified therein for research services related to Group's performance of the Study; and

 

WHEREAS, the parties agree to increase the support for the Study to offset the expenses of additional areas associated with [*] as set forth herein.

 

NOW, THEREFORE, the parties hereto, intending to be legally bound hereby, agree as follows:

 

	
 
	
A.
	
The following is added to Section 1.G of the Agreement:

 

The Company will provide financial support to the Group in the amount of $848,372 to support the activities associated with [*] for the Study as set forth in Exhibit E. The maximum financial support for the Agreement is increased from $23,448,570 by $848,372 to  $24,654,424.

 

	
 
	
B.
	
Exhibit B of the Agreement is deleted in its entirety and replaced by Exhibit B attached hereto.

 

	
 
	
C.
	
Exhibit E attached hereto is hereby added as Exhibit E of the Agreement thereto.

 

	
 
	
D.
	
This Amendment constitutes the full understanding of the parties and a complete and exclusive statement of the terms of their agreement with respect to the subject matter described herein, and no terms, conditions, understanding, or agreement purporting to modify or vary the terms of this Amendment shall be binding unless made in writing and signed by the parties.
	
 

 

 

 

	
 
	
E.
	
Except to the extent amended herein, all of the terms and conditions of the Agreement remain in full force and effect.
	
 

 

	
 
	
F.
	
Capitalized terms herein that are not defined shall have the meaning ascribed to such terms in the Agreement.
	
 

 

	
 
	
G.
	
This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which shall be considered one and the same instrument.
	
 

 

 

 

2

 
[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended 

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment, as of the Effective Date, by proper persons duly authorized.

 

ECOG-ACRIN Cancer Research GroupSyndax Pharmaceuticals, Inc.

 

 

/s/ Donna Marinucci/s/ Luke J. Albrecht

________________________________________________________________

Name: Donna MarinucciName: Luke J. Albrecht

Title: Executive DirectorTitle: General Counsel

 

3

 
[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended 

 

EXHIBITB

E2112 Budget & Payment Schedule

 

 

	
 
	
A.
	
Budget Details

 

	
 
	
1.
	
Budget – Excluding Amendments

 

The budget for this project is $19,406,948 which is itemized as follows:

 

[*]

 

	
 
	
2.
	
Budget – Amendment 1

 

The budget for Amendment 1 is $1,200,000 which is itemized as follows:

 

[*]

 

	
 
	
3.
	
Budget – Amendment 3 

 

The budget for Amendment 3 ([*] Support) is $450,000 which is itemized as follows:

 

[*]

 

	
 
	
4.
	
Budget – Amendment 4 

 

The budget for Amendment 4 ([*]) is $7,908 which is itemized as follows:

 

[*]

 

	
 
	
5.
	
Budget – Amendment 5

 

The budget for Amendment 5 is $30,121 which is itemized as follows:

 

[*]

 

[*] services being provided through Amendment 5 is limited to [*] of [*] services plus [*] of Group [*].

 

	
 
	
6.
	
Budget – Amendment 6

 

The budget for Amendment 6 is $287,438 which is itemized as follows:

 

[*]

 

	
 
	
7.
	
Budget – Amendment 7

 

The budget for Amendment 7 is $484,091 which is itemized as follows:

 

[*]

4

 
[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended 

 

 

	
 
	
8.
	
Budget – Amendment 8

 

The budget for Amendment 8 is $1,582,064 which is itemized as follows:

 

[*]

 

	
 
	
9.
	
Budget – Amendment 9

 

The budget for Amendment 9 is $357,482 which is itemized as follows:

 

[*]

 

	
 
	
10.
	
Invoicing and Payments

 

Company will make payments within [*] of receipt of invoices from Group according to the Payment Schedule herein. Payments will be made to as set forth in Section 1.B of the Agreement as follows:

 

ECOG Research and Education Foundation, Inc.

Agent for ECOG-ACRIN Cancer Research Group 

Attn:  Donna Marinucci

1818 Market Street, Suite 1100

Philadelphia, PA 19103

 

Group will send invoices to the following address: 

 

Jeannette Hasapidis 

VP, Program Management

Syndax Pharmaceuticals, Inc.

35 Gatehouse Rive, Building D, 3rd Flr

Waltham, MA 02451

 

	
 
	
B.
	
Payment Schedule – Excluding Amendments

Group will submit invoices to Company in accordance with the following Payment Schedule:

 

[*]

 

	
 
	
C.
	
Payment Schedule – Amendment 1

Group will submit invoices to Company in accordance with the following Payment Schedule:

 

[*]

 

	
 
	
D.
	
Payment Schedule – Amendment 3 ([*])

Group will submit invoices to Company in accordance with the following Payment Schedule:

 

[*]

 

	
 
	
E.
	
Payment Schedule – Amendment 4

Group will submit invoices to Company in accordance with the following Payment Schedule:

5

 
[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended 

 

 

[*]

 

	
 
	
F.
	
Payment Schedule – Amendment 5

Group will submit invoices to Company in accordance with the following Payment Schedule:

 

[*]

 

	
 
	
G.
	
Payment Schedule – Amendment 6

Group will submit invoices to Company in accordance with the following Payment Schedule:

 

[*]

 

	
 
	
H.
	
Payment Schedule – Amendment 7

Group will submit invoices to Company in accordance with the following Payment Schedule:

 

[*]

 

	
 
	
I.
	
Payment Schedule – Amendment 8

Group will submit invoices to Company in accordance with the following Payment Schedule:

 

[*]

 

	
 
	
J.
	
Payment Schedule – Amendment 9

Group will submit invoices to Company in accordance with the following Payment Schedule:

[*]

 

 

 

6

 
[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended 

 

EXHIBIT E

E2112 Scope of Work - Amendment 9

 

Protocol Title: A Randomized Phase Ill Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer

 

 

[*]

 

7

 
[*] = One page of confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]